[go: up one dir, main page]

TR201009398A2 - Tablet formulations with improved physical properties - Google Patents

Tablet formulations with improved physical properties

Info

Publication number
TR201009398A2
TR201009398A2 TR2010/09398A TR201009398A TR201009398A2 TR 201009398 A2 TR201009398 A2 TR 201009398A2 TR 2010/09398 A TR2010/09398 A TR 2010/09398A TR 201009398 A TR201009398 A TR 201009398A TR 201009398 A2 TR201009398 A2 TR 201009398A2
Authority
TR
Turkey
Prior art keywords
physical properties
improved physical
tablet formulations
locotriene
antihistaminic
Prior art date
Application number
TR2010/09398A
Other languages
Turkish (tr)
Inventor
Bi̇lgi̇ç Mahmut
Original Assignee
Bi̇lgi̇ç Mahmut
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bi̇lgi̇ç Mahmut filed Critical Bi̇lgi̇ç Mahmut
Priority to TR2010/09398A priority Critical patent/TR201009398A2/en
Priority to PCT/TR2011/000247 priority patent/WO2012064305A2/en
Priority to PCT/TR2011/000243 priority patent/WO2012064301A2/en
Publication of TR201009398A2 publication Critical patent/TR201009398A2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Mevcut buluş, derinin veya ust ve alt solunum yollarının alerjik ve inflamatuar hastalıklarının önlenmesi ve/veya tedavisinde ve bu hastalıklarla ilişkili semptomların giderilmesinde etkili bir Hı-antihıstamınik ve lokotrien reseptör antagonistı kombinasyonunu içermektedir.The present invention includes a combination of H1-antihistaminic and locotriene receptor antagonists effective in preventing and / or treating and relieving symptoms associated with allergic and inflammatory diseases of the skin or upper and lower respiratory tract.

TR2010/09398A 2010-11-11 2010-11-11 Tablet formulations with improved physical properties TR201009398A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
TR2010/09398A TR201009398A2 (en) 2010-11-11 2010-11-11 Tablet formulations with improved physical properties
PCT/TR2011/000247 WO2012064305A2 (en) 2010-11-11 2011-11-03 Formulations with improved physical characteristics
PCT/TR2011/000243 WO2012064301A2 (en) 2010-11-11 2011-11-03 Physically improved tablet formulations

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
TR2010/09398A TR201009398A2 (en) 2010-11-11 2010-11-11 Tablet formulations with improved physical properties

Publications (1)

Publication Number Publication Date
TR201009398A2 true TR201009398A2 (en) 2012-05-21

Family

ID=45446164

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2010/09398A TR201009398A2 (en) 2010-11-11 2010-11-11 Tablet formulations with improved physical properties

Country Status (2)

Country Link
TR (1) TR201009398A2 (en)
WO (2) WO2012064305A2 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5781606B2 (en) 2010-06-16 2015-09-24 インフラマトリー・レスポンス・リサーチ・インコーポレイテッド Use of levocetirizine and montelukast in the treatment of influenza, common colds and inflammation
RU2677649C2 (en) * 2013-02-21 2019-01-18 Глэнмарк Фармасьютикалс Лимитед Pharmaceutical compositions of montelucast and levocetirisine
AU2014249534B2 (en) 2013-03-13 2018-08-30 IRR, Inc. Use of levocetirizine and montelukast in the treatment of vasculitis
EP3300734B1 (en) 2013-03-13 2019-08-14 Inflammatory Response Research, Inc. Use of levocetirizine and montelukast in the treatment of autoimmune disorders
JP6313414B2 (en) * 2013-03-13 2018-04-18 インフラマトリー・レスポンス・リサーチ・インコーポレイテッド Use of levocetirizine and montelukast in the treatment of traumatic injury
CN106456535B (en) 2014-04-25 2020-07-03 R.P.谢勒技术有限公司 Stable montelukast solutions
JP2017526728A (en) 2014-09-15 2017-09-14 インフラマトリー・レスポンス・リサーチ・インコーポレイテッド Levocetirizine and montelukast in the treatment of inflammation-mediated conditions
PL3222279T3 (en) 2016-03-21 2022-05-09 Invest Bielany Spółka Z Ograniczoną Odpowiedzialnością Oral pharmaceutical formulation of montelukast and levocetirizine and method for its production
EP3463324A4 (en) * 2016-06-03 2020-01-29 Irr, Inc. Levocetirizine and montelukast in the treatment of radiation-mediated conditions
KR102110304B1 (en) * 2017-06-30 2020-05-14 한미약품 주식회사 Composite chewable tablet comprising levocetirizine and montelukast with improved stability and adaptability of taking medicine and a process for the preparation thereof
MX2018011699A (en) * 2018-09-26 2019-07-24 Federico Amezcua Amezcua A synergistic pharmaceutical composition of leukotriene receptor antagonist and a histamine h1 inverse agonist.
KR20210114962A (en) * 2019-01-10 2021-09-24 장인 무코케어 파마슈티컬 컴퍼니 리미티드 New formulations containing leukotriene receptor antagonists
EP4321156A4 (en) * 2021-10-21 2025-05-07 Han Wha Pharma Co., Ltd. Film-coated tablet with improved stability containing montelukaster or pharmaceutically acceptable salt thereof and levocetirizine or pharmaceutically acceptable salt thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK154078C (en) 1981-02-06 1989-05-22 Ucb Sa METHOD OF ANALOGUE FOR THE PREPARATION OF 2- (2- (4- (DIPHENYL-METHYL) -1-PIPERAZINYL) ETHOXY) -ACETAMIDES OR ACID ADDITION SALTS.
GB8827391D0 (en) 1988-11-23 1988-12-29 Ucb Sa Process for preparation of 2-(2-(4-((4-chlorophenyl)phenylmethyl)-1-pipera-zinyl)ethoxy)-acetic acid & its dihydrochloride
DK0480717T3 (en) 1990-10-12 1999-02-08 Merck Frosst Canada Inc Unsaturated hydroxyalkylquinoline acids as leukotriene antagonists
CA2145410A1 (en) 1992-09-24 1994-03-31 Nancy M. Gray Compositions for treating allergic disorders using (-) cetirizine
AU2003264859A1 (en) 2001-12-21 2003-12-19 Sampad Bhattacharya Intranasal pharmaceutical compositions comprising an antihistamine and a leukotriene inhibitor
EP1976522B2 (en) * 2005-12-30 2019-07-03 KRKA, tovarna zdravil, d.d., Novo mesto Pharmaceutical composition containing montelukast
RS51330B (en) 2006-02-09 2011-02-28 Teva Pharmaceutical Industries Ltd. STABLE PHARMACEUTICAL FORMULATIONS OF MONTELUKAST SODIUM
US20090124657A1 (en) * 2007-08-14 2009-05-14 Ramesh Kappala Pharmaceutical compositions comprising montelukast
WO2009122187A2 (en) * 2008-04-03 2009-10-08 Cipla Limited Pharmaceutical composition
WO2010107404A1 (en) * 2009-03-16 2010-09-23 Mahmut Bilgic Stable pharmaceutical combinations

Also Published As

Publication number Publication date
WO2012064305A2 (en) 2012-05-18
WO2012064305A3 (en) 2012-08-09
WO2012064301A3 (en) 2012-07-19
WO2012064301A2 (en) 2012-05-18

Similar Documents

Publication Publication Date Title
TR201009398A2 (en) Tablet formulations with improved physical properties
MX366018B (en) DEFICIENT T-CELL COMPOSITIONS OF THE T-CELL RECEPTOR.
PH12014502577A1 (en) Compositions comprising an anti-pdgf aptamer and a vegf antagonist
IL234508B (en) Inhalation of no and its use in the treatment of respiratory diseases in humans
BR112012027759A2 (en) GLP-1 AND GASTRIN RECEPTOR AGONIST PEPTIDE CONJUGATES AND THEIR USE
WO2015031808A3 (en) Diagnostic methods and compositions for treatment of glioblastoma
JO3462B1 (en) Human Antibodies to GFR?3 and methods of use thereof
DK2800581T3 (en) APPROACHES TO THE TREATMENT OF BEHAVIORAL SYMPTOMS OF NEUROLOGICAL AND MENTAL DISORDERS
CR20110658A (en) ANTAGONISTS OF THE HEDGEHOG CARE OF UNTITUTED FTALAZINA
IL221873A (en) History of pyrimidine and their use in the treatment of respiratory diseases such as copd
CU24133B1 (en) POLIPEPTIDES THAT LINK TO DR5 HUMAN WITH AGONIST EFFECTS, THAT INCLUDE ONE OR MORE MONOMERS OF A SINGLE VARIABLE DOMAIN, USEFUL IN THE TREATMENT OF DISEASES AND DISORDERS ASSOCIATED WITH DR5
LT4104824T (en) COMPOSITIONS FOR USE IN THE TREATMENT OF OVERWEIGHT AND OBESITY IN PATIENTS AT HIGH RISK OF CARDIOVASCULAR DISEASE
WO2013160317A3 (en) Crhr1 antagonists for use in the treatment of patients having crh overactivity
EP2799540A4 (en) HUMAN ARGINASE AND PEGYLATED HUMAN ARGINASE AND THEIR APPLICATION
EA201390977A1 (en) COMBINATION OF OPIOID RECEPTOR AGONIST AND OPIOID RECEPTOR ANTAGONIST FOR THE TREATMENT OF PARKINSON'S Disease
DK3065764T6 (en) Mini-gastrin analog, particularly for use in CCK-2 receptor positive tumor diagnosis and/or treatment
PT2501234T (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF SYMPTOMS ASSOCIATED WITH POST-TRAUMATIC STRESS DISORDERS USING CICLOBENZAPRINA
EP2990017A4 (en) PORTABLE DEVICE THAT CAN TREAT MALE DISEASE AND SIMILAR SYMPTOMS THEREOF
IL312551A (en) GRPR antagonists for the detection, diagnosis and treatment of GRPR-positive cancer
BR112012030331A2 (en) neuregulin isoforms, neuregulin polypeptides, and uses thereof
BR112015010039A2 (en) treatment of cancer with pomalidomide in an individual with renal dysfunction
TR201909158T4 (en) siRNA and its use in methods and compositions for the treatment and / or prevention of eye disorders.
EA201491532A1 (en) PHARMACEUTICAL COMPOSITIONS FOR USE IN COMPLEX THERAPY
CO6592047A2 (en) Topical ophthalmic peptide formulation
TR201900240T4 (en) Desmopressin to reduce nighttime urination.